“Miraca shares our mission of providing superior healthcare through better, more informed diagnostics, and I know that the patients and physicians we have served so well over the years will continue to benefit from outstanding diagnostic services under Miraca’s leadership,” said David D. Both parties emphasized that the clinician, patient and payor stakeholders will continue to receive the comprehensive, high-quality diagnostic services to which they are accustomed. “With the power of Caris’ successful, proven AP business, we will continue to provide the highest-quality diagnostic services in gastroenterology, dermatology, urology and hematology, and we look forward to both investing in and building the business going forward.”ĬLS and Miraca Holdings have worked together to ensure a seamless transition of CLS’ AP business. Hiromasa Suzuki, Ph.D., President and CEO of Miraca. Halbert and his team for their long-term investment in the world-class AP offerings that we have acquired,” said Dr. “Both companies are extremely well-positioned for the future, and we are grateful to Mr. The total purchase price was $725 million, including the repayment of the existing debt, subject to customary post-closing price adjustments. (“CDx,” a 100% subsidiary of CLS) and its subsidiaries and affiliates. 6, 2011, Miraca has acquired the AP business operated by Caris Diagnostics, Inc. As listed under the terms of the transaction, originally announced on Oct. (“CLS”), a privately-held company headquartered in Texas specializing in the development and commercialization of the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic technologies, today announced that they have completed the sale of CLS’ anatomic pathology (“AP”) business to Miraca. (“Miraca”), Japan’s largest clinical diagnostics and laboratory testing service provider, and Caris Life Sciences, Inc. Tokyo, Japan & Irving, Texas – Novem– Miraca Holdings Inc.
0 kommentar(er)
